Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models.
J Clin Invest
; 132(13)2022 07 01.
Article
en En
| MEDLINE
| ID: mdl-35775486
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Apirasa
/
Neoplasias
Límite:
Animals
Idioma:
En
Año:
2022
Tipo del documento:
Article